---
schema_version: "secwatch.filing_event.v1"
accession: "0001513162-22-000014"
form_type: "8-K"
ticker: "BMRA"
cik: "0000073290"
company_name: "BIOMERICA INC"
filed_at: "2022-02-10T23:59:59+00:00"
generated_at: "2026-06-27T09:22:49.941433+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomerica reports positive InFoods IBS endpoint trial results; multiple key endpoints show statistical significance

## Summary
- Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.
- Global Improvement Scale (GIS) endpoint p=0.040 for all patient subtypes (baseline vs 8 weeks).
- Abdominal Pain Intensity endpoint p=0.012 for IBS-Mixed & IBS-Constipation patients as a group.
- Bloating endpoint p=0.022 for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks).
- Company plans to meet with FDA to review results and finalize pivotal trial for FDA clearance.

## SEC filing metadata
- accession: 0001513162-22-000014
- form_type: 8-K
- ticker: BMRA
- cik: 0000073290
- company_name: BIOMERICA INC
- filed_at: 2022-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/73290/000151316222000014/0001513162-22-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/73290/000151316222000014/bmra-20220208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001513162-22-000014
- JSON: https://secwatch.observer/filing/0001513162-22-000014.json
- Plain text: https://secwatch.observer/filing/0001513162-22-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.